바이오스펙테이터

by Sungmin Kim

"Samsung Biologics plans to continue its innovation and growth"

Samsung Biologics announced today that John Rim, the company’s former Executive Vice President, has been appointed as the new President & Chief Executive Officer.

John Rim, the newly appointed CEO, brings more than 35 years of industry expertise and experience in biopharmaceuticals. Prior to joining Samsung Biologics, he served as the head of manufacturing, sales, development department, and as a CFO at global biotech companies like Roche and Genentech. He holds a master’s degree in Chemical engineering from Stanford University and earned an MBA from Northwestern University.

John Rim joined Samsung Biologics in September 2018 and has led Plant 3 business operations, the world’s largest manufacturing capacity at a single site. Owing to his professional experience and prior success, John Rim is expected to greatly contribute to building the company’s best in class capabilities in the market.

With the new leadership change, Samsung Biologics plans to continue its innovation and growth amid the challenging global business environment and the COVID-19 pandemic, whilst ensuring firm stability of its business operations.

Samsung Biologics is also planning to announce its 2021 Executive personnel appointment for the members below the Executive Vice President position in the coming weeks.